GlassScriptPhysician profile
Mark J Meiler
NPI 1235133158
$761.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $278 · 2021: $205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.37 | 2019-2021 | |
| Lilly USA, LLC | $94.79 | 2020-2021 | |
| Amgen INC. | $87.05 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.07 | 2019-2020 | |
| Abbvie INC. | $70.50 | 2021 | |
| Merck Sharp & Dohme LLC | $68.01 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $62.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $62.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.18 | 2020 | |
| Upsher-Smith Laboratories LLC | $19.45 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.11 | 2020 | |
| Aytu Biopharma, INC. | $14.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Meiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.